Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...

Inizio

Live Webinar: China in the fast lane: How to play and win in the world’s hottest emerging market

Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST

Inizio

- PMLiVE

Merck KGaA exec takes top job at UK biotech Kymab

UK biotech veteran returns to head antibody specialist

- PMLiVE

UniQure gets speedy US review for Huntington’s gene therapy

Pioneer gaining momentum again

- PMLiVE

Alnylam swaps Sanofi for Regeneron as R&D partner

Novel alliance between two biotechs

- PMLiVE

#OrkambiNow?

After a long standoff over CF treatment Orkambi, is a deal imminent?

scientific services porterhouse medical

Rewarding excellence within Porterhouse Medical’s scientific services team.

At Porterhouse Medical, we are very proud of our hard-working teams and are always delighted to recognise career progression within the agency. With this in mind, we are thrilled to...

Porterhouse Medical Group

Roche Basel Switzerland

Roche says ‘discovery proteomics’ is heading for clinical trials

Tech has potential to identify novel biomarkers

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

How to go BIG with your pharma exhibition stand design

At Apex, we believe that you don’t need to go for a huge exhibition stand if you want to get noticed. In fact, with a talented exhibition stand design team...

Apex Events and Exhibitions

- PMLiVE

Leader named for NHS digital transformation unit, but scepticism persists

NHS managers question logic of another authority

- PMLiVE

Celgene files luspatercept ahead of key merger vote

Analysts predict peak revenues of $2bn

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links